广东凯普生物科技股份有限公司股东云南众合之减持股份触及1%及5%整数倍，持股比例降至5%以下
关键信息摘要
- 持股5%以上股东云南众合之企业管理有限公司在已披露的减持计划范围内减持公司股份。
- 减持后，云南众合之持有凯普生物32,324,964股，占总股本的4.999989%，持股比例首次降至5%以下。
- 减持计划为2026年3月6日至6月5日之间，采取集中竞价及大宗交易方式，累计减持不超过19,395,000股（即不超过总股本的3%）。
- 本次减持区间为2026年5月12日至5月14日，期间累计减持431.48万股，持股比例由5.67%降至4.999989%。
- 云南众合之不是公司控股股东、实际控制人或其一致行动人，减持不会导致公司控制权变更，也不会对公司治理结构及持续经营产生重大影响。
- 减持过程与此前披露的减持计划一致，不存在违规及违反承诺情况。
- 自然人股东黄伟雄与谢龙旭均严格履行在公司IPO时作出的股份转让承诺。
- 减持计划尚未完全实施，公司将继续督促股东依法合规减持并及时披露。
详细解读与投资者关注重点
广东凯普生物科技股份有限公司（股票代码：300639）于2026年5月15日公告，其持股5%以上股东云南众合之企业管理有限公司（以下简称“云南众合之”）按照既定减持计划，在2026年5月12日至5月14日期间通过集中竞价和大宗交易方式累计减持公司股份431.48万股，持股比例由5.67%降至4.999989%，首次跌破5%的重要持股门槛。
此次减持是云南众合之根据2026年2月5日披露的减持预公告执行的，计划在2026年3月6日至6月5日间以不超过总股本3%的额度进行减持。其中，集中竞价方式每90天内不超过总股本的1%，大宗交易方式每90天内不超过总股本的2%。至本次公告日，云南众合之累计减持股份比例已触及1%及5%的整数倍。
股权变动对公司影响
- 云南众合之的减持行为不会导致公司控制权变更，也不会对公司治理结构和未来持续经营造成重大影响。
- 此次减持并未违反任何法律法规及公司相关承诺，且严格履行了信息披露义务。
- 黄伟雄和谢龙旭作为公司副董事长及职工代表董事，均未违反股份转让相关承诺。
投资者需重点关注事项
- 持股比例跌破5%对市场具有一定的敏感性，可能引发部分投资者对公司大股东信心的关注。
- 后续减持计划尚未完成，未来如有继续减持将持续影响市场情绪和股价波动。
- 公司董事会已承诺将督促股东依法合规减持，并及时履行信息披露义务。
总体来看，本次公告虽未涉及公司经营层面重大变化，但大股东持股降至5%以下具有一定的市场影响，投资者应关注减持计划的后续执行情况以及公司股权结构的进一步变化。
免责声明：本文仅为信息披露与投资者参考，不构成任何投资建议。投资者应结合自身情况和专业意见，审慎决策。公司及公告内容如有变动，以官方公告为准。
Guangdong Hybribio Biotechnology Co., Ltd. Shareholder Yunnan Zhonghezhi Reduces Shares Below 5%
Key Highlights
- Shareholder Yunnan Zhonghezhi, holding more than 5% shares, reduced its holding within the pre-disclosed plan.
- After reduction, Yunnan Zhonghezhi holds 32,324,964 shares, equivalent to 4.999989% of total shares, falling below the 5% threshold.
- The reduction plan covers March 6 to June 5, 2026, with a total not exceeding 19,395,000 shares (3% of total equity).
- Between May 12 and May 14, 2026, a total of 4.31 million shares were reduced, shrinking the shareholding from 5.67% to below 5%.
- Yunnan Zhonghezhi is neither the controlling shareholder nor the actual controller, so the reduction does not affect company control or governance.
- Reduction is consistent with the previously disclosed plan, with no violations or breaches of commitment.
- Natural person shareholders Huang Weixiong and Xie Longxu have strictly fulfilled their share transfer commitments since the IPO.
- The reduction plan is not yet completed, and the company will continue to supervise compliance and timely disclosure.
Detailed Analysis and Investor Focus
Guangdong Hybribio Biotechnology Co., Ltd. (stock code: 300639) announced on May 15, 2026, that Yunnan Zhonghezhi, a shareholder holding over 5%, executed its reduction plan from May 12 to May 14, reducing 4.31 million shares via block trade and auction. This drops its shareholding from 5.67% to under 5%, a key threshold for market monitoring.
The reduction is based on the plan disclosed on February 5, 2026, with a total reduction not exceeding 3% of company shares within three months. The reduction follows regulatory requirements for block trading (max 2% per 90 days) and auction (max 1% per 90 days). As of this disclosure, cumulative reductions have reached 1% and the 5% threshold.
Impact on Company
- The reduction does not change company control or governance structure.
- No violations or breaches of legal, regulatory, or prior commitments occurred.
- Key directors have fulfilled IPO share transfer promises.
Investor Attention Points
- Shareholding falling below 5% is market-sensitive and may impact investor confidence.
- Further reductions in the plan could continue to influence share price and market sentiment.
- The board will continue to supervise compliance and disclosure.
Overall, while no operational or governance changes have occurred, the drop below 5% by a major shareholder is significant for market sentiment and warrants investor attention regarding future reductions and shareholding structure changes.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should make decisions based on their own circumstances and professional counsel. Refer to official company disclosures for any updates.
